No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KRRO Korro Bio
- 38.320
- +5.210+15.74%
Close Jul 3 13:00 ET
- 38.000
- -0.320-0.84%
Post 16:20 ET
355.34MMarket Cap-3784P/E (TTM)
38.960High32.860Low50.54KVolume32.860Open33.110Pre Close1.85MTurnover1.28%Turnover RatioLossP/E (Static)9.27MShares97.91052wk High2.35P/B150.83MFloat Cap9.15052wk Low--Dividend TTM3.94MShs Float2918.500Historical High--Div YieldTTM18.42%Amplitude9.150Historical Low36.565Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Korro Bio Joins Russell 2000, Russell 3000 And Russell Microcap Indexes
Korro Joins the Russell 2000, Russell 3000, and Russell Microcap Indexes
CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly
BMO Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $120
BMO Capital analyst Kostas Biliouris maintains $Korro Bio(KRRO.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success rate of 31.0% and a
Korro to Participate in Upcoming June Investor and Scientific Conferences
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences:
Buy Rating Affirmed for Korro Bio Amid Promising KRRO-110 Preclinical Data and Superior Therapeutic Profile
Express News | HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $100 Price Target
Comments
This appointment strengthens Korro's board with the addition of Dr. Meyers' extensive experience in RNA-based medicines. This could potentially enhance Korro's ability to leverage their RNA editing platform and advance their lead product towards the clinic.
$Korro Bio(KRRO.US$ made money last week going to continue to trade ( only profits ) going into bonk coin.
all extra cash to xrp.
even though bitcoin, and Ethereum are being propped up, thinking over a long term XRPXLM will have the biggest returns over nxt 6 months
I am thankful for God, giving me another day to enjoy his beautiful creation and walk with him!
all extra cash to xrp.
even though bitcoin, and Ethereum are being propped up, thinking over a long term XRPXLM will have the biggest returns over nxt 6 months
I am thankful for God, giving me another day to enjoy his beautiful creation and walk with him!
$Korro Bio(KRRO.US$ market watch ,moomoo and Robinhood all have different prices right now for the same stock KRRO. One stock multiple prices……
$Korro Bio(KRRO.US$ i’ve traded this thing several times made some good money, but I can’t help going back. not risking as much now, but I feel like it’s about to run ?? oh well when this thing hits $49 tomorrow maybe 48 when I sell again thinking I’ll leave my profit in the form of free shares.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg